Merck and Moderna show cancer vaccine data at ESMO, a triumph of science

At the European Society for Medical Oncology conference in Madrid, Merck and Moderna presented data on their personalized cancer vaccine during the meeting’s presidential symposium, a session capable of seating thousands. According to Endpoints News, the hall was filled, reflecting broad clinical interest in the results.

Endpoints News reported that observers described the data as “a triumph of science,” language the outlet attributed to reaction at the session rather than to the companies’ own framing. The presentation addressed findings on the personalized cancer vaccine program that Merck and Moderna have developed jointly, work that has been closely watched across the oncology field for its implications for treating solid tumors.

The coverage noted that the scale of attendance at the presidential symposium itself signaled the level of anticipation among clinicians and researchers ahead of the data’s release. Endpoints News framed the moment as significant not only for the results shown in Madrid but for what comes next, describing the post-presentation period as the start of further work rather than a conclusion.

No additional trial specifics, efficacy figures, or patient population details were included in the available reporting. The account is limited to the setting, the scale of the audience, and the characterization of the data’s reception at the symposium, as conveyed by Endpoints News from the conference floor in Madrid.